US 7,744,867 B2 · PTPase inhibitors and method of using same

Abstract

The various embodiments of the present invention are directed to pentavalent antimonials, purified pentavalent antimonials, and pentavalent antimonials that are comprised of an antimonial portion and an organic moeity portion. Alternatively the present invention is directed to agents and methods of screening agents which mimic the activity of pentavalent antimonials, particularly sodium stibogluconate and glucatime. An appropriate organic moeity may be selected based upon a desired interaction (e.g. steric action) with active site of a cellular component (e.g. a PTPase). In a preferred embodiment of the present invention the active site includes a cysteine residue which may be impacted by the compositions of the present invention.

Claims18

Dependent claims

A therapeutic composition comprising:

(i) an effective amount of a pentavalent antimonial selected from the group consisting of glucantime and sodium stibogluconate, wherein said effective amount is from about 10 mg/kg to 140 mg/kg of said pentavalent antimonial;
and
(ii) further comprising an effective amount of IFN-α.

Dependencies are inferred from the claim text.

Facts

Application

10/159,473Filed 31 May 2002 · us provisional application

Priority

31 May 2001

Published

US 2003/0092670 A115 May 2003

Granted

29 Jun 2010

Term ends

Not estimatedThe source records don’t support an estimate.

Classification11 codes

A61K 31/29
Compounds containing heavy metals: antimony or bismuth compounds
A61K 31/39
Having sulfur as a ring hetero atom: having oxygen in the same ring
A61K 38/193
Cytokines; Lymphokines; Interferons: colony stimulating factors [CSF]
A61K 38/21
Cytokines; Lymphokines; Interferons: interferons [IFN]

PTPase inhibitors and method of using same

Life of this patent

PTPase inhibitors and method of using same

Life of this patent

Abstract

Claims18